CARY, N.C., August 20, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Merck & Co. as a specialty pharmacy provider for WELIREG™ (belzutifan) an inhibitor of hypoxia-inducible factor-2a (HIF-2a) indicated for the treatment of patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.
“Approximately 70% of patients who have VHL disease develop renal cell carcinoma during their lifetime,” said Ashleigh Burdette, senior director of Clinical Innovation for Biologics. “Before WELIREG, patients who developed RCC associated with VHL disease did not have a treatment option available to them. We are proud to work with Merck to help bring this novel therapy to patients in need.”
Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses and financial counselors. This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
###
About Biologics by McKesson
Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.